31.12 USD
↗ 0.63 (2.07%)AT CLOSE (03:59 PM EDT)
Pharvaris N.V. Ordinary Shares
PHVSNASDAQ • USD
30.97
↘ 0.15 (0.48%)
POST MARKET (AS OF 05:57 PM EDT)
Post Market
AS OF 05:57 PM EDT
30.97
↘ 0.15 (0.48%)
Market: OPEN
Shares of Pharvaris N.V. Ordinary Shares (PHVS) are trading at $30.97. The technical outlook is "Strong Sell" based on moving average alignment, RSI, and MACD signals. Key drivers include a bullish Golden Cross on the moving averages.
Technical & fundamental data as of Oct 6, 2026.
Open?$30.50
High?$31.27
Low?$30.15
Prev. Close?$30.49
Volume?778.4K
Avg. Volume?N/A
VWAP?$30.88
Bid / Ask
Bid?$26.44 × 100
Ask?$35.45 × 100
Spread?$9.01
Midpoint?$30.95
Valuation & Ratios
Market Cap?2.1B
Shares Out?65.4M
Float?38.1M
Float %?54.2%
P/E Ratio?N/A
P/B Ratio?N/A
EPS?N/A
Dividend?N/A
Ex-Dividend?N/A
News
Profile
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-1/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?– Neutral(0/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental Outlook
Loading...
Short InterestLow
Short % of Float?4.69%Low
Short Interest?1.8M
Days to Cover?1.2
Free Float38.1M
Avg Daily Volume1.4M
Settlement Date2026-09-15